Article
Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.
The oncologist - 1 Feb 2020
Saunders Ila M, Goodman Aaron M, Kurzrock Razelle
Abstract excerpt
BACKGROUND: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis. The BRAF inhibitor vemurafenib is approved by the U.S. Food and Drug Administration (FDA) for patients with ECD harboring a BRAF V600E mutation. Successful treatment has also been reported with MEK-targeted therapies, likely because of the fact that BRAF mutant-negative patients harbor MEK pathway alterations. In our Rare Tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.